2021
DOI: 10.20944/preprints202102.0496.v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia

Abstract: Non-coding RNAs (ncRNAs) comprise a diverse class of non-protein coding transcripts that regulate critical cellular processes associated with cancer. Advances in RNA-sequencing (RNA-Seq) have led to the characterization of non-coding RNA expression across different types of human cancers. Through comprehensive RNA-Seq profiling, a growing number of studies demonstrate that ncRNAs, including long non-coding RNA (lncRNAs) and microRNAs (miRNA), play central roles in progenitor B-cell Acute Lymphoblastic Leukemia… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 89 publications
0
5
0
Order By: Relevance
“…A hiPS cell line harboring the leukemia‐specific fusion gene ETV6‐RUNX1 [Takahashi and Yamazaki, 2019 ] would be useful for focusing on the participation of MFs in the development of leukemia from a pre‐leukemic state. Moreover, determining whether MFs contribute to some mechanisms of leukemogenesis without genetic changes, namely epigenetic alterations such as DNA methylation [Dunwell et al, 2009 ], histone modification [Li et al, 2010 ; Swaroop et al, 2019 ], and alterations of noncoding RNAs [Rodriguez et al, 2021 ], is also crucial.…”
Section: Discussionmentioning
confidence: 99%
“…A hiPS cell line harboring the leukemia‐specific fusion gene ETV6‐RUNX1 [Takahashi and Yamazaki, 2019 ] would be useful for focusing on the participation of MFs in the development of leukemia from a pre‐leukemic state. Moreover, determining whether MFs contribute to some mechanisms of leukemogenesis without genetic changes, namely epigenetic alterations such as DNA methylation [Dunwell et al, 2009 ], histone modification [Li et al, 2010 ; Swaroop et al, 2019 ], and alterations of noncoding RNAs [Rodriguez et al, 2021 ], is also crucial.…”
Section: Discussionmentioning
confidence: 99%
“…123 BARL2 overexpression is also associated with poor therapeutic response and OS in B-ALL patients. 85…”
Section: Lncrnas In Leukemiamentioning
confidence: 99%
“…Moreover, Rao et al noted that the expression patterns of BARL2 (B‐ALL–associated long RNAs‐2) lncRNA could predict three common cytogenetic profiles of B‐ALL (ETV6‐RUNX1, TCF3‐PBX1, and MLL‐AF4) 123 . BARL2 overexpression is also associated with poor therapeutic response and OS in B‐ALL patients 85 …”
Section: Lncrnas In Human Diseasesmentioning
confidence: 99%
“…Commonly, oncogenic miRNAs (oncomiRs) are overexpressed in cancers while tumor-suppressive miRNAs (tsmiRs) are lowly expressed. miRNAs have additionally been identified as candidates for diagnostic and prognostic biomarkers, as well as predictors of drug responses in cancer [25,26]. Importantly, miRNAs represent candidate clinical biomarkers that may act as indicators of relapse for B-ALL [26][27][28].…”
Section: Introductionmentioning
confidence: 99%
“…miRNAs have additionally been identified as candidates for diagnostic and prognostic biomarkers, as well as predictors of drug responses in cancer [25,26]. Importantly, miRNAs represent candidate clinical biomarkers that may act as indicators of relapse for B-ALL [26][27][28]. However, there have been limited number of such studies and new clinically relevant biomarkers are still needed.…”
Section: Introductionmentioning
confidence: 99%